International Stem Cell CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
International Stem Cell Corporation's 10-K filing reveals a 17% increase in product sales driven by biomedical market growth, alongside ongoing efforts in therapeutic development and a going concern uncertainty.
OQB
10-K: International Stem Cell Corporation Files 10-K Report, Cites Ongoing Losses and Need for Capital
International Stem Cell Corporation's annual 10-K filing reveals continued operating losses and a reliance on commercial businesses to fund research and development, while highlighting progress in clinical trials for Parkinson's disease.